MedTrace Logo

Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury

NCT01676441 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-03-23

No results posted yet for this study

Summary

This phase II/III clinical trial is designed to evaluate the safety and efficacy of autologous Mesenchymal Stem Cells (MSC) transplanted directly into the injured spinal cord.

Conditions

  • Spinal Cord Injury

Interventions

DRUG

cellgram-spine

Mesenchymal stem cells transplantation

Sponsors & Collaborators

  • Pharmicell Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Sangryong Jeon, MD, PhD · Asan Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2021-03-04
Completion
2021-03-04

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01676441 on ClinicalTrials.gov